Nanoform launches technology for biologics and sets new near-term business target for 2021

Nanoform launches technology for biologics and sets new near-term business target for 2021

Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a proprietary technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.